Program
cromolyn
Also written as “Cromoglicate”, “Cromolyn Sodium (34.2 mg BID)” and “Cromolyn Sodium (17.1 mg BID)”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Adenocarcinoma of Lung · Psoriasis · Mastocytosis, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AZTherapies | 40 open or running | phase 3since Sep 10, 2015 | Sep 10, 2015 | none ahead |
| LEO Pharma | 20 open or running | phase 2since Jul 11, 2012 | Jul 11, 2012 | none ahead |
| Carcinex | 11 open or running | phase 1since Jun 16, 2026 | Jun 16, 2026 | Jun 2027phase 1 · NCT07675876 |
| PhenoNet | 11 open or running | phase 2since Aug 19, 2025 | Aug 19, 2025 | Mar 2027phase 2 · NCT07142291 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2012First study: phase 2 study in MastocytosisNew to LEO PharmaLEO Pharma · NCT01701843 · 7 enrolled · Germany
- Nov 5, 2012Phase 2 study in PsoriasisLEO Pharma · NCT01722812 · 30 enrolled · Germany
- Sep 10, 2015AZTherapies's first study: phase 3 study in Alzheimer DiseaseNew to AZTherapiesAZTherapies · NCT02547818 · 620 enrolled · United States, Australia, Bulgaria and more
- Jun 26, 2017Phase 2 study in Ischemic StrokeAZTherapies · NCT03202147
- Jun 3, 2020Phase 2 study in Amyotrophic Lateral SclerosisAZTherapies · NCT04428775 · 12 enrolled · United States
- Sep 17, 2020Phase 1 study in Alzheimer DiseaseAZTherapies · NCT04570644 · 56 enrolled · United States
- Aug 19, 2025PhenoNet's first study: phase 2 study in Amyotrophic Lateral SclerosisNew to PhenoNetPhenoNet · NCT07142291 · 105 planned · United States, Czechia, Germany and more
- Jun 16, 2026Carcinex's first study: phase 1 study in Adenocarcinoma of LungNew to CarcinexCarcinex · NCT07675876 · 10 planned · United States
Ahead
- Mar 2027Primary completion: phase 2 study in Amyotrophic Lateral SclerosisPhenoNet · NCT07142291
- Jun 2027Primary completion: phase 1 study in Adenocarcinoma of LungCarcinex · NCT07675876
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07675876Adenocarcinoma of Lung · United States | 1 | Not yet recruiting | Carcinex | Jun 2027 | 10 |
| NCT07142291Amyotrophic Lateral Sclerosis · United States, Czechia, Germany and more | 2 | Recruiting | PhenoNet | Mar 2027 | 105 |
| NCT04570644Alzheimer Disease · United States | 1 | Completed | AZTherapies | Jan 18, 2021 | 56 |
| NCT04428775Amyotrophic Lateral Sclerosis · United States | 2 | Terminated | AZTherapies | Oct 1, 2021 | 12 |
| NCT03202147Ischemic Stroke | 2 | Withdrawn | AZTherapies | Dec 2024 | 0 |
| NCT02547818Alzheimer Disease · United States, Australia, Bulgaria and more | 3 | Completed | AZTherapies | Nov 13, 2020 | 620 |
| NCT01722812Psoriasis · Germany | 2 | Completed | LEO Pharma | Apr 2013 | 30 |
| NCT01701843Mastocytosis · Germany | 2 | Terminated | LEO Pharma | Feb 2013 | 7 |
How it is read
Names in the registry
- “Cromoglicate”, 2 entries
- “Cromolyn Sodium (34.2 mg BID)”, 1 entry
- “Cromolyn Sodium (17.1 mg BID)”, 1 entry
- “Cromolyn Sodium”, 1 entry
- “ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 2 studies
- Alzheimer Disease, 2 studies
- Adenocarcinoma of Lung, 1 study
- Psoriasis, 1 study
- Mastocytosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.